Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IID572: A New Potentially Best-In-Class β-Lactamase Inhibitor

12 Mar 2019

Abstract excerpt

Resistance in Gram-negative bacteria to β-lactam drugs is mediated primarily by the expression of β-lactamases, and co-dosing of β-lactams with a β-lactamase inhibitor (BLI) is a clinically proven strategy to address resistance. New β-lactamases that are not impacted by existing BLIs are spreading and creating the need for development of novel broader spectrum BLIs. IID572 is a novel broad spectrum BLI of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antibiotic Use and Resistance
Share to Antibiotics Pharmacokinetics and Efficacy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30861342
DOI: 10.1021/acsinfecdis.9b00031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IID572: A New Potentially Best-In-Class β-Lactamase InhibitorPMID 30861342Read ↗

Recent advances in the development of β-lactamase inhibitorsSemantic proximity Read ↗

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With SulbactamSemantic proximity Read ↗

Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical UseSemantic proximity Read ↗

Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitorsSemantic proximity Read ↗

QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological CharacteristicsSemantic proximity Read ↗

The role of new β-lactamase inhibitors in gram-negative infectionsSemantic proximity Read ↗

Discovery of ANT3310 , a Novel Broad-Spectrum Serine β-Lactamase Inhibitor of the Diazabicyclooctane Class, Which Strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter baumanniiSemantic proximity Read ↗

Genomic approach to evaluate the intrinsic antibacterial activity of novel diazabicyclooctanes (zidebactam and nacubactam) against clinical Escherichia coli isolates from diverse clonal lineages in the United Arab EmiratesSemantic proximity Read ↗

Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamasesSemantic proximity Read ↗

Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance.Semantic proximity Read ↗

Beta-lactams and Beta-lactamase-inhibitors in current- or potential-clinical practice: A comprehensive updateSemantic proximity Read ↗

Diversity and Proliferation of Metallo-β-Lactamases: a Clarion Call for Clinically Effective Metallo-β-Lactamase InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.